Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 187


The Role of Local Therapy in Multi-focal Epithelioid Haemangioendothelioma.

Tong D, Constantinidou A, Engelmann B, Chamberlain F, Thway K, Fisher C, Hayes A, Fotiadis N, Messiou C, Miah AB, Zaidi SH, Benson C, VAN DER Graaf W, Jones RL.

Anticancer Res. 2019 Sep;39(9):4891-4896. doi: 10.21873/anticanres.13675.


Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin.

Jones RL, Maki RG, Patel SR, Wang G, McGowan TA, Shalaby WS, Knoblauch RE, von Mehren M, Demetri GD.

Cancer. 2019 Sep 10. doi: 10.1002/cncr.32462. [Epub ahead of print]


Sarcomas and old age: few options for such a large patient population.

Jones RL.

Future Oncol. 2019 Sep 10. doi: 10.2217/fon-2019-0489. [Epub ahead of print]


First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1.

Somaiah N, Block MS, Kim JW, Shapiro GI, Do KT, Hwu P, Eder JP, Jones RL, Lu H, Ter Meulen JH, Bohac C, Chen M, Hsu FJ, Gnjatic S, Pollack SM.

Clin Cancer Res. 2019 Jun 21. doi: 10.1158/1078-0432.CCR-19-1025. [Epub ahead of print]


Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas).

Sanfilippo R, Jones RL, Blay JY, Le Cesne A, Provenzano S, Antoniou G, Mir O, Fucà G, Fumagalli E, Bertulli R, Stacchiotti S, Brahmi M, Grosso F, Dufresne A, Hindi N, Sbaraglia M, Gronchi A, Collini P, Dei Tos AP, Casali PG.

Clin Cancer Res. 2019 Sep 1;25(17):5295-5300. doi: 10.1158/1078-0432.CCR-19-0288. Epub 2019 Jun 19.


Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma.

Berlow NE, Rikhi R, Geltzeiler M, Abraham J, Svalina MN, Davis LE, Wise E, Mancini M, Noujaim J, Mansoor A, Quist MJ, Matlock KL, Goros MW, Hernandez BS, Doung YC, Thway K, Tsukahara T, Nishio J, Huang ET, Airhart S, Bult CJ, Gandour-Edwards R, Maki RG, Jones RL, Michalek JE, Milovancev M, Ghosh S, Pal R, Keller C.

BMC Cancer. 2019 Jun 17;19(1):593. doi: 10.1186/s12885-019-5681-6.


Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial.

Zhang S, Kohli K, Black RG, Yao L, Spadinger SM, He Q, Pillarisetty VG, Cranmer LD, Van Tine BA, Yee C, Pierce RH, Riddell SR, Jones RL, Pollack SM.

Cancer Immunol Res. 2019 Aug;7(8):1237-1243. doi: 10.1158/2326-6066.CIR-18-0940. Epub 2019 Jun 6.


Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial.

Younger E, Ballman K, Lu Y, Pápai Z, Van Tine BA, Attia S, Schöffski P, Reinke D, Tap WD, Jones RL.

J Geriatr Oncol. 2019 May 22. pii: S1879-4068(18)30464-8. doi: 10.1016/j.jgo.2019.05.008. [Epub ahead of print]


Pazopanib in advanced soft tissue sarcomas.

Lee ATJ, Jones RL, Huang PH.

Signal Transduct Target Ther. 2019 May 17;4:16. doi: 10.1038/s41392-019-0049-6. eCollection 2019. Review.


A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas.

Jones RL, Chawla SP, Attia S, Schöffski P, Gelderblom H, Chmielowski B, Le Cesne A, Van Tine BA, Trent JC, Patel S, Wagner AJ, Chugh R, Heyburn JW, Weil SC, Wang W, Viele K, Maki RG.

Cancer. 2019 Jul 15;125(14):2445-2454. doi: 10.1002/cncr.32084. Epub 2019 Apr 29.


Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.

Chamberlain FE, Wilding C, Jones RL, Huang P.

Expert Opin Investig Drugs. 2019 Jun;28(6):505-511. doi: 10.1080/13543784.2019.1607291. Epub 2019 Apr 22. Review.


Aldoxorubicin in soft tissue sarcomas.

Chamberlain FE, Jones RL, Chawla SP.

Future Oncol. 2019 May;15(13):1429-1435. doi: 10.2217/fon-2018-0922. Epub 2019 Mar 15. Review.


Treatment of Desmoid Tumors in 2019.

Gronchi A, Jones RL.

JAMA Oncol. 2019 Apr 1;5(4):567-568. doi: 10.1001/jamaoncol.2018.6449. No abstract available.


Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients.

Sebio A, Constantinidou A, Benson C, Antoniou G, Messiou C, Miah A, Zaidi S, Petruckevitch A, Al-Muderis O, Thway K, VAN DER Graaf WT, Jones RL.

Anticancer Res. 2019 Jan;39(1):347-351. doi: 10.21873/anticanres.13118.


Ending 40 years of silence: Rationale for a new staging system for soft tissue sarcoma of the head and neck.

Hahn E, Huang SH, Hosni A, Razak AA, Jones RL, Dickson BC, Sturgis EM, Patel SG, O'Sullivan B.

Clin Transl Radiat Oncol. 2018 Nov 27;15:13-19. doi: 10.1016/j.ctro.2018.11.009. eCollection 2019 Feb. Review.


Optimising Cancer Vaccine Design in Sarcoma.

Pender A, Jones RL, Pollack S.

Cancers (Basel). 2018 Dec 20;11(1). pii: E1. doi: 10.3390/cancers11010001. Review.


Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma.

Jones RL, Mo G, Baldwin JR, Peterson PM, Ilaria RL Jr, Conti I, Cronier DM, Tap WD.

Cancer Chemother Pharmacol. 2019 Jan;83(1):191-199. doi: 10.1007/s00280-018-3723-4. Epub 2018 Nov 8.


Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review.

Riedel RF, Jones RL, Italiano A, Bohac C, Thompson JC, Mueller K, Khan Z, Pollack SM, Van Tine BA.

Cancers (Basel). 2018 Nov 1;10(11). pii: E417. doi: 10.3390/cancers10110417. Review.


Age-related sarcoma patient experience: results from a national survey in England.

Younger E, Husson O, Bennister L, Whelan J, Wilson R, Roast A, Jones RL, van der Graaf WT.

BMC Cancer. 2018 Oct 17;18(1):991. doi: 10.1186/s12885-018-4866-8.


Trends in Modern Phase 1 Oncology Trials.

Jones RL.

N Engl J Med. 2018 Sep 20;379(12):1188-9. doi: 10.1056/NEJMc1808907. No abstract available.


Supplemental Content

Loading ...
Support Center